Children with acute lymphoblastic T-cell leukaemia (T-ALL) who relapse after allogeneic stem cell transplantation (SCT) have limited treatment options and a poor prognosis. 1 Immune checkpoint inhibitors targeting the programmed death (PD-1) receptor pathway may enhance the GvL effect by blockade of inhibitory signals to T cells mediated by its ligand PD-L1. 2 There has been limited experience with the use of checkpoint inhibitors in haematologic malignancies post allogeneic SCT, especially concerning the (re)activation of GvHD. [3] [4] [5] [6] [7] Recently, Singh et al. 5 reported a patient receiving anti-PD-1 treatment for refractory Hodgkin's lymphoma after allogeneic SCT who developed fatal GvHD. Previous reports of anti-PD-1 treatment post SCT demonstrated no induction of GvHD post SCT. However, these patients had no previous acute or chronic GvHD. 4, 7, 8 We report the case of a 9-year-old girl with refractory T-ALL after allogeneic SCT treated off-label with the PD-1 inhibitor pembrolizumab. At the age of 10 years, she was diagnosed with T-ALL (8.2 g/L WBC, 82% bone marrow infiltration, central nervous system (CNS) negative, t(6;11)) and treated according to the high-risk protocol of the COALL 08/09 study. A minimal residual disease (MRD) marker was identified by real-time PCR for clonespecific TCR rearrangements. 9 Despite an intensified chemotherapeutic regimen including clofarabin and nelarabin, molecular remission was not achieved and the MRD marker remained positive (4 × 10
). Therefore, SCT was performed as a curative treatment option for this patient. 10 After myeloablative conditioning consisting of 12 Gy TBI, VP16 and cyclophosphamide, she underwent HLA-haploidentical bone marrow transplantation from her mother, and received post-transplant cyclophosphamide, tacrolimus and mycophenolate mofetil. The last MRD level before transplantation was 4 × 10
. On day 100 post SCT, she had a donor chimerism of 100% and decreasing MRD level (minimal 1 × 10
). Her post-transplant course was complicated by acute GvHD grade I involving the skin, which was treated successfully with topical and systemic corticosteroids. A few weeks later she developed thrombotic microangiopathy and posterior reversible encephalopathy syndrome in combination with arterial hypertension. She had a molecular relapse with an MRD of 5 × 10 − 3 and a subsequent morphological relapse as well as mixed donor chimerism (95%)-140 days post SCT. Further treatment regimens included chemotherapy (vincristine and mercaptopurine), intrathecal therapy (methotrexate) and four donor lymphocyte infusions (DLIs). Initially, she displayed a good morphological response to DLIs, but the leukaemic burden eventually remained stable with an MRD of 2 × 10
. Considering 54.2% PD-1 expression on T lymphocytes in the patient's bone marrow and the encouraging data in other haematologic malignancies, an off-label therapy with the PD-1 inhibitor pembrolizumab was started (see Supplementary Material: Antibody Panel). 11 The patient and her parents gave informed consent and she received a single dose of pembrolizumab at 3.3 mg/kg 343 days after SCT. One week after administration she developed acute GvHD grade IV of the skin, mucosa, liver, lung, CNS and eyes. She had a severe generalised inflammatory reaction with high markers (C-reactive protein (CrP) max. (Figure 2) . Pseudomembranous conjunctivitis consistent with GvHD and subtotal corneal erosion of the right eye was diagnosed. Treatment with high-dose corticosteroids, cyclosporine and the anti-IL-6 receptor Ab tocilizumab led to a slight improvement of her clinical condition. The following cerebral MRI showed regressive periventricular white matter lesions but new hyperintensities of basal ganglia, bilateral temporal lobe and cerebellum. Her MRD value 2 weeks after administration decreased significantly to 4 × 10 − 4 and she again achieved a 100% donor chimerism in bone marrow. Despite this promising response, her medical condition deteriorated and the severe inflammatory reaction led to multi-organ failure worsened by Staphylococcus aureus sepsis. She suffered from cardiorespiratory decompensation, and required cardiopulmonary resuscitation followed by a continuous therapy with vasopressors and venovenous haemodialysis. After initiating immunosuppressive treatment with dexamethasone and cyclosporine, the MRD re-increased to 5 × 10 − 3 in the bone marrow 50 days after PD-1 blockade. Because of her poor prognosis, her parents decided to reduce the treatment to palliative care and she passed away shortly thereafter.
The presented case is the first one to our knowledge to report a remarkable and fast response to PD-1 inhibition followed by a severe lethal inflammatory disease and GvHD of the skin, liver, lung, CNS and eyes in the setting of a paediatric T-ALL patient post allogeneic SCT. This clinical course and intensity of acute GvHD was similar to the patient reported by Singh et al. 5 Other reports of patients treated with immune checkpoint inhibitors (ipilimumab, pidilizumab and nivolumab) after allogeneic SCT, showed no exacerbation or reactivation of GvHD. 3, 4, 12 In a recently published study of 28 patients with haematologic malignancies receiving ipilimumab after allogeneic SCT, three patients developed chronic GvHD of the liver and one patient developed acute GvHD of the gut. 6 In contrast to our patient presented above, all of the symptoms resolved with glucocorticoids. It should be noted that all these SCTs reported were from matched-related or -unrelated donors and not from haploidentical donors. It is still unclear which factors trigger the GvHD reaction and which are preventive. The risk of GvHD re(activation) due to PD-1/PD-L1 inhibition might be more severe during the early phase post transplantation. Our patient received pembrolizumab 12 months after the SCT, which was earlier than in previously described cases. 4, 7 In addition, the haploidentical donor type may have increased the risk for severe GvHD. Until now, there is no standardised treatment option for refractory T-ALL available, indicating an urgent need for new therapeutic approaches. Since the MRD response in the patient described here was very promising, it will be important to gain more information and experience regarding the efficient and safe treatment with PD-1 inhibitors post allogeneic SCT.
